607376-66-9

Upstream product

• 57471-70-2 diethyl N-benzyloxycarbonyl-(S)-aspartate 
• 116-11-0 2-Methoxypropene 
• 118219-23-1 [(1S)-3-hydroxy-1-(hydroxymethyl)propyl]carbamic acid phenylmethyl ester 
• 192517-47-8 methyl (3S)-3-[[(benzyloxy)carbonyl]amino]-4-hydroxybutanoate 
• 3160-47-2 N-(benzyloxycarbonyl)-L-aspartic acid 4-methyl ester 
• 837410-82-9 methyl (4S)-(3-benzyloxycarbonyl-2,2-dimethyl-1,3-oxazolidin-4-y)acetate 
• 77-76-9 2,2-dimethoxy-propane 

Downstream Products

• 837410-97-6 methyl 5-benzyloxycarbonylamino-6-oxo-1-hydropyridine-2-carboxylate 
• 837410-99-8 methyl 5-benzyloxycarbonylamino-6-methoxypyridine-2-carboxylate 
• 837410-95-4 methyl (5S)-5-benzyloxycarbonylamino-6-oxo-1,4,5-trihydropyridine-2-carboxylate 
• 837411-10-6 methyl 5-benzyloxycarbonylamino-3-bromo-6-methoxypyridine-2-carboxylate 
• 837411-13-9 methyl 5-benzyloxycarbonylamino-3,6-dimethoxypyridine-2-carboxylate 
• 837411-07-1 methyl (5S)-5-benzyloxycarbonylamino-3-bromo-6-oxo-1-hydropyridine-2-carboxylate 
• 837411-04-8 methyl (5S)-5-benzyloxycarbonylamino-3-bromo-6-oxo-,4,5-trihydropyridine-2-carboxylate 
• 837410-90-9 methyl (6RS,5S)-5-benzyloxycarbonylamino-6-hydroxy-1-t-butoxycarbonyl-4,5,6-trihydropyridine-2-carboxylate 
• 837410-93-2 methyl (5S)-5-benzyloxycarbonylamino-6-oxo-1-t-butoxycarbonyl-4,5,6-trihydropyridine-2-carboxylate 
• 837410-88-5 methyl (5S,2Z)-5-benzyloxycarbonylamino-2-t-butoxycarbonylamino-6-hydroxy-2-hexenoate 
• 837410-85-2 methyl (5S,2Z)-4-(3-benzyloxycarbonyl-2,2-dimethyl-1,3-oxazolidin-4-yl)-2-t-butoxycarbonylamino-2-butenoate 
• 1602828-00-1 C₃₅H₄₅N₃O₈S₂ 
• 1602827-71-3 C₃₅H₄₅N₃O₈S₂ 
• 1602827-74-6 C₂₆H₃₂N₂O₇S 

Relevant academic research and scientific papers

A concise [C+NC+CC] coupling-enabled synthesis of kaitocephalin

A 15-step synthesis of the iGluR antagonist kaitocephalin from aspartic acid is reported. The linchpin pyrrolidine ring of the target molecule is efficiently assembled with in a single operation via an asymmetric [C+NC+CC] reaction.

BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS

The invention is concerned with novel bicyclic compounds of formula (I), wherein A, L, E, F, G, R1, R2, R3, R4, R5, R6, R7, V, W and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compound

NOVEL BICYCLIC COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein A, L, E, F, G, R1, R2, R3, R4, R5, R6, R7, V, W and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

Useful synthesis of 2,3,6-tri- and 2,3,5,6-tetrasubstitutedpyridine derivatives from aspartic acid

New synthetic methods for 2,3,6-tri- and 2,3,5,6-tetrasubstituted pyridineskeletons, which are the essential main central segments of thiostrepton-type macrocyclic antibiotics, were developed from l-α-aspartic acid (Asp) via the Asp-derived α-dehydroamino

3-(Imidazolyl)-2-aminopropanoic acids

Compounds according to formula (I) wherein n is 1-4, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3,